There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cigna (CI – Research Report), Replimune Group (REPL – Research Report) and Alnylam Pharma (ALNY – Research Report) with bullish sentiments.
Cigna (CI)
Barclays analyst Steven Valiquette reiterated a Buy rating on Cigna yesterday and set a price target of $355.00.
According to TipRanks.com, Valiquette is a 2-star analyst with an average return of
Cigna has an analyst consensus of Moderate Buy, with a price target consensus of $322.50.
See today’s best-performing stocks on TipRanks >>
Alnylam Pharma (ALNY)
In a report released yesterday, Gena Wang from Barclays maintained a Buy rating on Alnylam Pharma, with a price target of $236.00. The company’s shares closed last Thursday at $190.10.
According to TipRanks.com, Wang is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alnylam Pharma with a $258.27 average price target, which is a 41.8% upside from current levels. In a report issued on July 24, Bank of America Securities also maintained a Buy rating on the stock with a $262.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CI:
